Patterns of Progression, Subsequent Therapy in the CLEAR Trial

Viktor Grünwald, MD, PhD, of University Hospital Essen, showcases the latest updates from the CLEAR study on patterns of progression and subsequent therapy for patients receiving lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma.

He considers the factors that may contribute to the observed differences in progression patterns, as well as how these findings may influence first-line therapy choices in this patient population.